Ultragenyx Pharmaceutical Inc. (RARE)

48.77
2.50 5.30
NASDAQ : Health Technology
Prev Close 46.31
Open 46.40
Day Low/High 46.40 / 50.35
52 Wk Low/High 41.67 / 91.34
Volume 292.04K
Avg Volume 548.60K
Exchange NASDAQ
Shares Outstanding 47.53M
Market Cap 2.24B
EPS -6.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest In Ultragenyx Pharmaceutical Drops 16%

The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 919,934 share decrease in total short interest for Ultragenyx Pharmaceutical Inc , to 4,819,058, a decrease of 16.03% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Ultragenyx Pharmaceutical Inc. - RARE

Newman Ferrara LLP Announces Corporate Governance Investigation Of Ultragenyx Pharmaceutical Inc. - RARE

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Positive Interim Topline Results From First Cohort Of Phase 1/2 Clinical Study Of DTX301 Gene Therapy In Ornithine Transcarbamylase (OTC) Deficiency 

Ultragenyx Announces Positive Interim Topline Results From First Cohort Of Phase 1/2 Clinical Study Of DTX301 Gene Therapy In Ornithine Transcarbamylase (OTC) Deficiency 

Early Evidence of Normalization of Ureagenesis in One Patient in Lowest-Dose Cohort and Acceptable Initial Safety Profile

Ultragenyx Announces Update To UX007 Development Program In Long-Chain Fatty Acid Oxidation Disorder Patients

Ultragenyx Announces Update To UX007 Development Program In Long-Chain Fatty Acid Oxidation Disorder Patients

Ultragenyx to Provide Additional Information to FDA for Consideration of Possible Early Filing on Current Phase 2 Data

Ultragenyx And Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion For The Treatment Of X-Linked Hypophosphatemia In Children

Ultragenyx And Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion For The Treatment Of X-Linked Hypophosphatemia In Children

If approved, Burosumab would be the first targeted disease-modifying treatment for XLH

Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

The Cambridge, Mass.-based Ironwood unveiled top-line data from a pair of Phase 2a studies evaluating IW-1973 in patients that have type 2 diabetes and hypertension.

Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab (KRN23) In X-Linked Hypophosphatemia

Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab (KRN23) In X-Linked Hypophosphatemia

Further improvement in disease symptoms and fracture healing observed through 48 weeks of treatment with burosumab

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

The hotly debated tax reform championed by the Trump White House needs to be paid for by spending cuts. One proposed change could eliminate the tax credit for companies developing treatments through the Orphan Drug Act.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AINV, AMOT, ANIP, EXFO, EXPR, INBK, LIND, LNN, LTM, MJCO, MYRG, SGEN, WEYS Downgrades: BAM, ESRT, IAG, PGRE, RRTS, SSRM Initiations: RARE Read on to get TheStreet Quant Ratings' detailed report:

Ultragenyx And Kyowa Hakko Kirin Announce FDA Not Currently Planning To Hold Advisory Committee Meeting For Burosumab Biologics License Application

Ultragenyx And Kyowa Hakko Kirin Announce FDA Not Currently Planning To Hold Advisory Committee Meeting For Burosumab Biologics License Application

Regulatory Review Process Proceeding as Expected; PDUFA date of April 17, 2018

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.

TheStreet Quant Rating: D (Sell)